NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer - NICE TAG TA284

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer - NICE TAG TA284

Please note that NICE can only issue guidance on any drug within the terms of its marketing authorisation. Consequently, bevacizumab for first-line treatment of advanced ovarian cancer has only been appraised at its licensed dose of 15 mg/kg body weight.

1.1 Bevacizumab in combination with paclitaxel and carboplatin is not recommended for first-line treatment of advanced ovarian cancer (International Federation of Gynaecology and Obstetrics [FIGO] stages IIIB, IIIC and IV epithelial ovarian, fallopian tube or primary peritoneal cancer).

1.2 People currently receiving bevacizumab for first-line treatment of advanced ovarian cancer should be able to continue treatment until they and their clinicians consider it appropriate to stop.

 

https://www.nice.org.uk/guidance/TA284

Site by Devopa
© Copyright 2019 NHS. All rights reserved.